瑞舒伐他汀预防冠状动脉支架术后再狭窄的疗效及其对血脂和CRP的影响

目的分析并评价瑞舒伐他汀预防冠状动脉支架术后再狭窄的疗效及其对血脂和C反应蛋白(CRP)的影响。方法将2011年12月至2012年12月在湛江中心人民医院就诊的急性冠状动脉综合征患者212例按用药不同分为两组,其中瑞舒伐他汀组(108例)给予常规治疗+10 mg/d的瑞舒伐他汀治疗,常规治疗组(104例)给予常规治疗。比较两组患者支架植入术后再狭窄率及手术前后血脂及CRP水平的变化。结果两组患者在用药期内均未见肌痛、肝功及血肌酸激酶异常。术后6个月,常规治疗组患者心绞痛复发率及再狭窄率显著高于瑞舒伐他汀组(P<0.05);瑞舒伐他汀组患者术后血脂及CRP的水平较术前及常规治疗组有显著差异(P<0.05)。结论瑞舒伐他汀在预防冠状动脉支架术后再狭窄以及调节血脂方面的效果理想,无明显不良反应,建议长期服用。

Curative Effect of Rosuvastatin in the Prevention of Restenosis after Coronary Stent Implantation and Its Effect on Blood Lipid and CRP

Objective To analyze and evaluate the curative effect of rosuvastatin in preventing restenosis after coronary artery stent implantation and its effects on blood lipid and C-reactive protein.Methods A total of 212 cases of patients with acute coronary syndrome admitted in Zhanjiang Central People＇s Hospital from Dec.2011 to Dec.2012 were randomly divided into two groups：patients in rosuvastatin group were given conventional treatment and 10 mg/d of rosuvastatin,while patients in the conventional treatment group received routine treatment.The incidence rate of restenosis after operation,the levels of blood lipid and CRP before and after operation of the two groups were compared.Results There was no incidence of myalgia,and abnormality of creatine kinase and liver functionfound in the two groups during the period of treatment.Six months after operation,recurrence rates of angina pectoris and restenosis of the conventional treatment group were significantly higher than those of rosuvastatin group（P ＜ 0.05）.The levels of blood lipid and CRP of rosuvastatin group after operation were significantly different from those before treatment and those of the conventional treatment group （P ＜ 0.05）.Conclusion The curative effect of rosuvastatin in the prevention of restenosis after coronary stent implantation and its effect on the regulation of blood lipid level was ideal,without significant adverse reactions,therefore,rosuvastatin is recommended for long-term use.